Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia
Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The study aims to confirm that a reduced dosage of GCSF is effective in preventing febrile
neutropenia among patients with breast cancer, treated with chemotherapy and presenting with
a low to moderate risk of developing febrile neutropenia.